Skip to main content
Log in

Evolution of dose and response to botulinum toxin A in cervical dystonia: a multicenter study

  • Original Communication
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

Botulinum neurotoxin (BoNT) is an effective treatment for cervical dystonia (CD). Long-term changes of several variables, including the dose of BoNT, in these patients is largely unknown. We reviewed the clinical charts of 275 patients with CD treated with BoNT type A (BoNT-A) for at least 5 years since 1989 at ten tertiary centers. The mean dose of BoNT-A per session during the first 5 years of treatment was calculated and the appearance of resistance was noted. The dose of BoNT-A for the whole group showed a significant trend to increase over time (year 1: 180 ± 65 U; year 5: 203 ± 63 U; ANOVA: p < 0.0001). However, when we studied the evolution of the dose of BoNT-A for those patients (n = 49) first injected after 2000 (introduction of current BOTOX preparation in our country), there was no significant increase in dose (year 1: 181.8 ± 75 U; year 5: 181.7 ± 75 U; ANOVA p: ns). A total of 19 patients became secondary nonresponders; all but one of these patients began BoNT-A treatment before 2000. In summary, there is a statistically significant increase of mean dose of BoNT-A per session over time, and this could be explained by the appearance of secondary nonresponders. On the other hand, those patients initially treated after 2000 did not show any statistically significant increase in dose for 5 years. This could be explained by better experience and techniques, fewer immunogenic problems with the current BoNT-A, and also less variability of the dose per vial.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fukuda H, Kusumi M, Nakashima K (2006) Epidemiology of primary focal dystonias in the western area of Tottori prefecture in Japan: comparison with prevalence evaluated in 1993. Mov Disord 21:1503–1506

    Article  PubMed  Google Scholar 

  2. Tsui JK, Eisen A, Stoessl AJ, Calne S, Calne DB (1986) Double blind study of botulinum toxin in spasmodic torticollis. Lancet 2:245–247

    Article  PubMed  CAS  Google Scholar 

  3. Gelb D, Lowenstein D, Aminoff M (1989) Controlled trial of botulinum toxin injections in the treatment of spasmodic torticollis. Neurology 39:80–84

    PubMed  CAS  Google Scholar 

  4. Jankovic J, Schwartz K (1990) Botulinum toxin injections for cervical dystonia. Neurology 40:277–280

    PubMed  CAS  Google Scholar 

  5. Costa J, Espírito-Santo C, Borges A, Ferreira JJ, Coelho M, Moore P, Sampaio C (2005) Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev 25(1):CD003633

    Google Scholar 

  6. Mejia N, Vuong K, Jankovic J (2005) Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord 20:592–597

    Article  PubMed  Google Scholar 

  7. Greene P, Fahn S, Diamond B (1994) Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 9:213–217

    Article  PubMed  CAS  Google Scholar 

  8. Jankovic J, Schwartz K (1995) Response and immuneresistance to botulinum toxin injections. Neurology 45:1743–1746

    PubMed  CAS  Google Scholar 

  9. Sankhla C, Jankovic J, Duane D (1998) Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections. Mov Disord 13:150–154

    Article  PubMed  CAS  Google Scholar 

  10. Cordivari C, Misra VP, Vincent A, Catania S, Bhatia KP, Lees AJ (2006) Secondary nonresponsiveness to botulinum toxin A in cervical dystonia: the role of electromyogram-guided injections, botulinum toxin A antibody assay, and the extensor digitorum brevis test. Mov Disord 21:1737–1741

    Article  PubMed  Google Scholar 

  11. Brin MF, Comella CL, Jankovic J, Lai F, Naumann M, for the CD-017 BoNTA Study Group (2008) Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord 23:1353–1360

    Article  PubMed  Google Scholar 

  12. Jankovic J, Vuong KD, Ahsan J (2003) Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 60:1186–1188

    PubMed  CAS  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Juan Carlos Martínez Castrillo.

Additional information

P. J. Garcia Ruiz and J. C. Martínez Castrillo contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Garcia Ruiz, P.J., Martínez Castrillo, J.C., Burguera, J.A. et al. Evolution of dose and response to botulinum toxin A in cervical dystonia: a multicenter study. J Neurol 258, 1055–1057 (2011). https://doi.org/10.1007/s00415-010-5880-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-010-5880-1

Keywords

Navigation